IP Library Granted Patent US 12,558,240
Granted Patent B2
US 12,558,240 · App. 18/929,399 · Granted Feb 24, 2026

Aortic arch baroreceptor implants for treatment of hypertension

Inventors: Farrell O. Mendelsohn (Birmingham, AL); Craig Bonsignore (Scottsdale, AZ)
Assignee: ARCHimedes Vascular, Inc.
A61F2/856A61F2/06A61F2002/061A61F2002/068A61F2/90A61F2210/0014A61F2230/0008A61F2230/0017A61F2250/0039
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,558,240
App. No.
18/929,399
Granted
Feb 24, 2026
Kind
B2
Abstract

Implant devices for hypertension and methods of treatment are provided. Implant devices are configured for placement in a target region of an aortic arch of the patient, thereby engaging arterial walls in the target region sufficiently to stretch and/or tension arterial walls, thereby inducing the baroreflex response. Such implants can include one or more expandable structures configured to engage an elongated target region in the aortic arch. The target region can extend along a majority of the aortic arch including a cylindrical segment of aortic arch between the left common carotid artery and the left subclavian artery. An elongated target zone can further extend at least between the brachiocephalic artery takeoff and the left subclavian artery takeoff. Such embodiments can utilize one or more expandable structures with a non-circular cross-section that stretch and reshape the arterial walls to induce tension in the arterial walls, thereby generating a robust baroreflex response.

Claims (22)

1 . A method for treating hypertension in a patient, said method comprising:

deploying an implant within an aortic arch of the patient, the implant having a collapsed configuration for advancement through a vasculature of the patient and an expanded configuration for engagement of an arterial wall within the aortic arch of the patient, the implant having a length of at least 60 mm when deployed;

engaging the arterial wall with the implant in the expanded configuration along a target zone that includes a region that extends at least between a brachiocephalic artery takeoff and a left subclavian artery takeoff, wherein the implant has a non-circular cross-section when expanded thereby inducing wall tension along the target zone in the aortic arch;

exposing a majority of the arterial wall along the target zone to pulsatile blood flow via side openings of the implant so as to induce a long term baroreflex response;

wherein the implant is woven or braided from one or more wires; and

wherein, in the expanded configuration, the side openings each having an area of 9 mm 2 or greater to allow blood flow therethrough to any lateral arteries in the aortic arch and to expose arterial walls to pulsatile blood flow.

2 . The method of claim 1 , wherein the non-circular cross-section is elliptical.

3 . The method of claim 1 , wherein the non-circular cross-section is a regular polygonal shape.

4 . The method of claim 1 , wherein the non-circular cross-section is constant along an entire length of the implant.

5 . The method of claim 1 , wherein the length when deployed is between 60-100 mm.

6 . The method of claim 5 , wherein the implant is dimensioned so that a greatest lateral dimension is greater than 25 mm.

7 . The method of claim 1 , wherein the implant is self-expandable.

8 . The method of claim 1 , wherein the one or more wires are Nitinol.

9 . A method for treating hypertension in a patient, said method comprising:

deploying an implant within an aortic arch of the patient, the implant having a collapsed configuration for advancement through a vasculature of the patient and an expanded configuration for engagement of an arterial wall within the aortic arch of the patient, the implant having a length of at least 60 mm when deployed;

engaging the arterial wall with the implant in the expanded configuration along a target zone that includes a region that extends at least between a brachiocephalic artery takeoff and a left subclavian artery takeoff, wherein the implant has a non-circular cross-section when in the expanded configuration thereby inducing an increased wall tension along the target zone in the aortic arch and, wherein the implant includes expandable structure segments connected serially by multiple flexible connectors to allow the expandable structure segments to extend axially along a curvature of the aortic arch, and wherein, when the implant is deployed, the expandable structure segments positioned at a proximal end and a distal end of the implant have a diameter greater than a diameter of an expandable structure segment located at a mid-section of the implant to thereby prevent migration of the implant; and

exposing a majority of the arterial wall along the target zone to pulsatile blood flow via side openings of the expandable structure segments in order to induce a long term baroreflex response.

10 . A method for treating hypertension in a patient, said method comprising:

deploying an implant within an aortic arch of the patient, the implant having a collapsed configuration for advancement through a vasculature of the patient and an expanded configuration for engagement of an arterial wall within the aortic arch of the patient, the implant having a length of at least 60 mm;

engaging the arterial wall with the implant in the expanded configuration along a target zone that corresponds to an area of baroreceptor nerves and includes a region that extends at least between a brachiocephalic artery takeoff and a left subclavian artery takeoff, wherein the implant has a non-circular cross-section when in the expanded configuration thereby inducing increased wall tension along the target zone in the aortic arch;

exposing a majority of the arterial wall along the target zone to pulsatile blood flow via side openings of the implant in order to induce a long term baroreflex response; and

wherein the implant includes a middle expandable structure is that at the target location to activate the baroreceptor nerves, and wherein the implant further includes a proximal expandable anchor and a distal expandable anchor to secure the middle structure in the target zone.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2026
From: ARCHIMEDES VASCULAR, LLC
To: ARCHIMEDES VASCULAR, INC.
Reel/Frame 073857/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2026
From: ARCHIMEDES VASCULAR, LLC
To: ARCHIMEDES VASCULAR, INC.
Reel/Frame 073857/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2024
From: MENDELSOHN, FARRELL O.; BONSIGNORE, CRAIG
To: ARCHIMEDES VASCULAR, LLC
Reel/Frame 069059/0782 →
Continuity (6)
Continuation In Part PCTUS2023020612 · May 1, 2023
Provisional Application 63657565 · Jun 7, 2024
Provisional Application 63594903 · Oct 31, 2023
Provisional Application 63443656 · Feb 6, 2023
Provisional Application 63336818 · Apr 29, 2022
Related Publication 20250049557A1 · Feb 13, 2025
References Cited (72)
US 5104404A · Wolff · 1992 [cited by applicant]
US 5755781A · Jayaraman · 1998 [cited by applicant]
US 6875228B2 · Pinchasik et al. · 2005 [cited by applicant]
US 8257430B2 · Mead · 2012 [cited by applicant]
US 8454677B2 · Fischell · 2013 [cited by examiner]
US 8663541B2 · Chun et al. · 2014 [cited by applicant]
US 8923972B2 · Gross · 2014 [cited by applicant]
US 9125567B2 · Gross et al. · 2015 [cited by applicant]
US 9125732B2 · Gross et al. · 2015 [cited by applicant]
US 9402751B2 · Zukowski · 2016 [cited by applicant]
US 9457174B2 · Gross · 2016 [cited by applicant]
US 9550048B2 · Gross · 2017 [cited by applicant]
US 9592136B2 · Gross et al. · 2017 [cited by applicant]
US 9642726B2 · Gross et al. · 2017 [cited by applicant]
US 10279184B2 · Pierce et al. · 2019 [cited by applicant]
US 10384043B2 · Gross et al. · 2019 [cited by applicant]
US 10588763B2 · Kassab et al. · 2020 [cited by applicant]
US 10653513B2 · Seybold et al. · 2020 [cited by applicant]
US 10779965B2 · Dagan et al. · 2020 [cited by applicant]
US 10786372B2 · Yeh et al. · 2020 [cited by applicant]
US 20030093142A1 · Edelman et al. · 2003 [cited by applicant]
US 20060149353A1 · Schatz et al. · 2006 [cited by applicant]
US 20070005127A1 · Boekstegers et al. · 2007 [cited by applicant]
US 20080177350A1 · Kieval et al. · 2008 [cited by applicant]
US 20100042202A1 · Ramzipoor et al. · 2010 [cited by applicant]
US 20100179614A1 · Kieval et al. · 2010 [cited by applicant]
US 20110077729A1 · Gross et al. · 2011 [cited by applicant]
US 20110230957A1 · Bonsignore et al. · 2011 [cited by applicant]
US 20120232613A1 · Kieval et al. · 2012 [cited by applicant]
US 20130304102A1 · Gross et al. · 2013 [cited by applicant]
US 20130338748A1 · Dagan · 2013 [cited by applicant]
US 20150073533A1 · Kassab et al. · 2015 [cited by applicant]
US 20160303381A1 · Pierce et al. · 2016 [cited by applicant]
US 20170135829A1 · Gross et al. · 2017 [cited by applicant]
US 20170196713A1 · Gross et al. · 2017 [cited by applicant]
US 20170304042A1 · Ren · 2017 [cited by applicant]
US 20180235745A1 · Seybold et al. · 2018 [cited by applicant]
US 20190224484A1 · Pierce et al. · 2019 [cited by applicant]
US 20190247050A1 · Goldsmith · 2019 [cited by applicant]
US 20200384248A1 · Gross et al. · 2020 [cited by applicant]
US 20210007837A1 · Haldis · 2021 [cited by examiner]
US 20210077283A1 · Yeh et al. · 2021 [cited by applicant]
US 20220183865A1 · Gifford, III · 2022 [cited by examiner]
US 20220257279A1 · Deaton · 2022 [cited by examiner]
CN 109009562A · 2018 [cited by applicant]
DE 19611755A1 · 1998 [cited by applicant]
EP 0828461A1 · 1998 [cited by applicant]
EP 1006938A1 · 2000 [cited by applicant]
EP 2471491A2 · 2012 [cited by applicant]
WO 2009118912A1 · 2009 [cited by applicant]
WO 2020214110A1 · 2020 [cited by applicant]
Abraham, “The Structure of Baroreceptors in Pathological Conditions in Man”, Baroreceptors and Hypertension, 1967, pp. 273-291. [cited by applicant]
Armour, “Physiological Behavior of Thoracic Cardiovascular Receptors”, American Journal of Physiology, vol. 225, No. 1, Jul. 1973, pp. 177-185. [cited by applicant]
Aumonier, “Histological Observations on the Distribution of Baroreceptors in the Carotid and Aortic Regions of the Rabbit, Cat and Dog”, Acta Anatomica, vol. 82, No. 1, 1972, pp. 1-16. [cited by applicant]
Benson et al., “Aortic Arch Baroreceptor Stimulation in an Experimental Goat Model: A Novel Method to Lower Blood Pressure”, Frontiers in Cardiovascular Medicine, vol. 5, No. 193, Jan. 15, 2019, 7 pages. [cited by applicant]
Bergwerff et al., “Unique Vascular Morphology of the Fourth Aortic Arches: Possible Implications for Pathogenesis of Type-B Aortic Arch Interruption and Anomalous Right Subclavian Artery”, Cardiovascular Research, vol. … [cited by applicant]
Daly et al., “The Localisation of Receptors Involved in the Reflex Regulation of the Heart Rate”, From the Institute of Physiology, Cardiff, and the Laboratories of the Medical Unit, University College Hospital Medical … [cited by applicant]
Donald et al., “Comparison of Aortic and Carotid Baroreflexes in the Dog”, J. Physiol., 215, pp. 521-538. [cited by applicant]
Hauss et al., “Uber die Reizung der Pressorezeptoren im Sinus Caroticus Beim Hund”, Zeitschrift fur Kreislaufforschung, vol. 38, 1949, pp. 28-33. [cited by applicant]
Kember et al., “Mechanism of Smart Baroreception in the Aortic Arch”, Physical Review E: Statistical, Nonlinear, and Soft Matter Physics, vol. 74, Sep. 2006, 5 pages. [cited by applicant]
Krauhs, “Structure of Rat Aortic Baroreceptors and Their Relationship to Connective Tissue”, Journal of Neurocytology, vol. 8, Aug. 1979, pp. 401-414. [cited by applicant]
Lau et al., “Aortic Baroreceptors Display Higher Mechanosensitivity Than Carotid Baroreceptors”, Frontiers in Physiology, vol. 7, No. 384, Aug. 31, 2016, 8 pages. [cited by applicant]
Lauder et al., “Device-Based Therapies for Arterial Hypertension”, Nature Reviews Cardiology, vol. 17, Oct. 2020, pp. 614-628. [cited by applicant]
Mahfoud et al., “Device Therapy of Hypertension”, Circulation Research, vol. 128, No. 7, Apr. 2, 2021, pp. 1080-1099. [cited by applicant]
Mendelowitz et al., “Pulsatile Sinus Pressure Changes Evoke Sustained Baroreflex Responses in Awake Dogs”, American Journal of Physiology, vol. 255, Sep. 1988, pp. H673-H678. [cited by applicant]
Min et al., “Arterial Baroreceptors Sense Blood Pressure Through Decorated Aortic Claws”, Supplemental Information, Cell Reports, vol. 29, No. 8, Nov. 19, 2019, 11 pages. [cited by applicant]
Min et al., “Arterial Baroreceptors Sense Blood Pressure Through Decorated Aortic Claws”, Cell Reports, vol. 29, No. 8, Nov. 19, 2019, pp. 2192-2201.e3. [cited by applicant]
Sanders et al., “Arterial baroreflex control of sympathetic nerve activity during elevation of blood pressure in normal man: dominance of aortic baroreflexes”, Pathophysiology and Natural History—Hypertension, vol. 77, … [cited by applicant]
Spiering et al., “Endovascular Baroreflex Amplification for Resistant Hypertension: A Safety and Proof-of-Principle Clinical Study”, Lancet, vol. 390, No. 10113, Dec. 16, 2017, pp. 2655-2661. [cited by applicant]
Sutton et al., “Archives of Internal Medicine”, Pain, vol. 45, No. 6, 1930, pp. 827-867. [cited by applicant]
Van Kleef et al., “Endovascular baroreflex amplification and the effect on sympathetic nerve activity in patients with resistant hypertension: A proof-of-principle study”, PLoS ONE 16(11): e0259826, Nov. 16, 2021, 1-14. [cited by applicant]
Zangirolami et al., “Ortner's Syndrome: Secondary Laryngeal Paralysis Caused by a Great Thoracic Aorta Aneurysm”, International Archives of Otorhinolaryngology, vol. 19, No. 2, Apr. 2015, pp. 180-182. [cited by applicant]